Limits...
Establishment and characterization of a receptor-negative, hormone-nonresponsive breast cancer cell line from an Iraqi patient.

Al-Shammari AM, Alshami MA, Umran MA, Almukhtar AA, Yaseen NY, Raad K, Hussien AA - Breast Cancer (Dove Med Press) (2015)

Bottom Line: The anchorage-independent growth ability test showed that the cells were able to grow in semisolid agarose, confirming their transformed nature.Immunocytochemistry showed that the estrogen receptor and the progesterone receptor were not expressed, and a weak positive result was found for HER2/neu gene expression.AMJ13 cells were positive for BRCA1 and BRCA2, as well as for vimentin.

View Article: PubMed Central - PubMed

Affiliation: Experimental Therapy Department, Iraqi Center for Cancer and Medical Genetic Research, Mustansiriya University, Baghdad, Iraq.

ABSTRACT
A new breast cancer cell line (AMJ13) has been established from an Iraqi breast cancer patient. It is considered unique because it is the first for an Iraqi population, and is expected to be a useful tool in breast cancer research. The AMJ13 cell line was established from the primary tumor of a 70-year-old Iraqi woman with a histological diagnosis of infiltrating ductal carcinoma. The cells were morphologically characterized by light and scanning electron microscopy, and found to be elongated multipolar epithelial-like cells with a population doubling time of 22 hours. The anchorage-independent growth ability test showed that the cells were able to grow in semisolid agarose, confirming their transformed nature. Cytogenetic study of these cells showed chromosomal aberrations with many structural and numerical abnormalities, producing chromosomes of unknown origin called marker chromosomes. Immunocytochemistry showed that the estrogen receptor and the progesterone receptor were not expressed, and a weak positive result was found for HER2/neu gene expression. AMJ13 cells were positive for BRCA1 and BRCA2, as well as for vimentin. This cell line should be useful when testing new therapies for breast cancer in the Middle East.

No MeSH data available.


Related in: MedlinePlus

Immunocytochemistry analysis of AMJ13 cell line.Notes: (A) Negative result for ER (magnification 40×). (B) Negative result for PR (magnification 40×). (C) Weak positive result for Her-neu2 gene expression (magnification 40×). (D) BRCA1-positive nuclear staining of breast cancer epithelial cells (magnification 40×). (E) BRCA2-positive nuclear and cytoplasmic staining of breast cancer cells (magnification 40×). (F) Vimentin marker-positive cells (magnification 40×). (G) Negative control.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4536763&req=5

f8-bctt-7-223: Immunocytochemistry analysis of AMJ13 cell line.Notes: (A) Negative result for ER (magnification 40×). (B) Negative result for PR (magnification 40×). (C) Weak positive result for Her-neu2 gene expression (magnification 40×). (D) BRCA1-positive nuclear staining of breast cancer epithelial cells (magnification 40×). (E) BRCA2-positive nuclear and cytoplasmic staining of breast cancer cells (magnification 40×). (F) Vimentin marker-positive cells (magnification 40×). (G) Negative control.

Mentions: ER, PR, and Her-neu2 gene expression in the AMJ13 breast cancer cell line was detected using an anti-mouse IgG immunocytochemistry kit (Figure 8A–C). The results showed that the cells were negative for ER and PR, and weakly positive for Her-neu2 gene expression when compared with a negative control. Rabbit anti-mouse BRCA1 and BRCA2 genes and vimentin were used to detect these important markers. AMJ13 cells were positive for BRCA1 nuclear staining, but to a lesser degree than BRCA2, which was positive for both nuclear and cytoplasmic staining (Figure 8D and E). Vimentin was strongly positive (Figure 8F).


Establishment and characterization of a receptor-negative, hormone-nonresponsive breast cancer cell line from an Iraqi patient.

Al-Shammari AM, Alshami MA, Umran MA, Almukhtar AA, Yaseen NY, Raad K, Hussien AA - Breast Cancer (Dove Med Press) (2015)

Immunocytochemistry analysis of AMJ13 cell line.Notes: (A) Negative result for ER (magnification 40×). (B) Negative result for PR (magnification 40×). (C) Weak positive result for Her-neu2 gene expression (magnification 40×). (D) BRCA1-positive nuclear staining of breast cancer epithelial cells (magnification 40×). (E) BRCA2-positive nuclear and cytoplasmic staining of breast cancer cells (magnification 40×). (F) Vimentin marker-positive cells (magnification 40×). (G) Negative control.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4536763&req=5

f8-bctt-7-223: Immunocytochemistry analysis of AMJ13 cell line.Notes: (A) Negative result for ER (magnification 40×). (B) Negative result for PR (magnification 40×). (C) Weak positive result for Her-neu2 gene expression (magnification 40×). (D) BRCA1-positive nuclear staining of breast cancer epithelial cells (magnification 40×). (E) BRCA2-positive nuclear and cytoplasmic staining of breast cancer cells (magnification 40×). (F) Vimentin marker-positive cells (magnification 40×). (G) Negative control.
Mentions: ER, PR, and Her-neu2 gene expression in the AMJ13 breast cancer cell line was detected using an anti-mouse IgG immunocytochemistry kit (Figure 8A–C). The results showed that the cells were negative for ER and PR, and weakly positive for Her-neu2 gene expression when compared with a negative control. Rabbit anti-mouse BRCA1 and BRCA2 genes and vimentin were used to detect these important markers. AMJ13 cells were positive for BRCA1 nuclear staining, but to a lesser degree than BRCA2, which was positive for both nuclear and cytoplasmic staining (Figure 8D and E). Vimentin was strongly positive (Figure 8F).

Bottom Line: The anchorage-independent growth ability test showed that the cells were able to grow in semisolid agarose, confirming their transformed nature.Immunocytochemistry showed that the estrogen receptor and the progesterone receptor were not expressed, and a weak positive result was found for HER2/neu gene expression.AMJ13 cells were positive for BRCA1 and BRCA2, as well as for vimentin.

View Article: PubMed Central - PubMed

Affiliation: Experimental Therapy Department, Iraqi Center for Cancer and Medical Genetic Research, Mustansiriya University, Baghdad, Iraq.

ABSTRACT
A new breast cancer cell line (AMJ13) has been established from an Iraqi breast cancer patient. It is considered unique because it is the first for an Iraqi population, and is expected to be a useful tool in breast cancer research. The AMJ13 cell line was established from the primary tumor of a 70-year-old Iraqi woman with a histological diagnosis of infiltrating ductal carcinoma. The cells were morphologically characterized by light and scanning electron microscopy, and found to be elongated multipolar epithelial-like cells with a population doubling time of 22 hours. The anchorage-independent growth ability test showed that the cells were able to grow in semisolid agarose, confirming their transformed nature. Cytogenetic study of these cells showed chromosomal aberrations with many structural and numerical abnormalities, producing chromosomes of unknown origin called marker chromosomes. Immunocytochemistry showed that the estrogen receptor and the progesterone receptor were not expressed, and a weak positive result was found for HER2/neu gene expression. AMJ13 cells were positive for BRCA1 and BRCA2, as well as for vimentin. This cell line should be useful when testing new therapies for breast cancer in the Middle East.

No MeSH data available.


Related in: MedlinePlus